Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Markets
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon May 21, 2021 2:49pm
214 Views
Post# 33249100

RE:RE:RE:RE:RE:RE:RE:Markets

RE:RE:RE:RE:RE:RE:RE:Markets
WalkOverTheStrt wrote:

Mugs 
Not tracking this "I can only assume their patent life is much greater than the 5 years remaining for OTENA" 
Otenal loses US exclusivity in 2032. slide 20 https://antibethera.com/wp-content/uploads/2021/04/Antibe-Corporate-Presentation-April-2021.pdf

BTW funny story on SAVA - had 3K shares / $9 avg pps and bought right after the posiitve earlier PH2 study only to watch the stock tank to $3 as the ph2b studies were not solid - ended up being a testing issue with the lab or something (I sold a few weeks after the drop) and then watch the stock jump as it did... Als is a larger market potential but highly risky as no drugs to date have impressed, 



Depending when we actually come to market ... if later than expected for any delay ... we will get a minimum of 5 years in USA and 7 years in Europe (or shomething like that).  That's all I meant by that comment.

No drugs to date have impressed - agreed - but I'm banking on H2S making a big difference as per the studies on H2S for AD as we shared here in the past.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities